The articles in this eBook examine key trends driving this transformation, from AI-enabled discovery and experimental validation to advanced cell, gene, and biologic platforms, and explore how the ...
當秋意漸濃的微風拂過日本橫濱港灣，PACIFICO 橫濱國際會展中心（PACIFICO Yokohama）再次成為全球生命科學領域目光聚焦的交會點。作為亞洲歷史悠久且規模盛大的生技媒合對接平台，2026 年日本生技大展（BioJapan ...
Researchers at the Institute of Science and Technology Austria (ISTA) have identified a mechanism in the gut bacterium ...
First-in-human study evaluates dual-target, dual-payload ADC in advanced ovarian cancer and other solid tumours Phrontline ...
Minimal residual disease ctDNA testing in metastatic breast cancer patients with no radiological evidence of disease: Potential clinical utility from real-world data. Clinicopathologic features and ...
CAMBRIDGE, Mass., May 14, 2026 /PRNewswire/ -- Ring Therapeutics®, a life sciences company pioneering a new class of targeted medicines, today announced new data on its Vector Conjugate platform and ...
The data, which are being presented as a poster and an oral presentation at the 29th Annual American Society of Gene & Cell Therapy (ASGCT) conference, highlight significantly increased cargo capacity ...
Antibody-drug conjugates (ADCs) have emerged as one of the most impactful therapeutic advances in modern oncology, fundamentally reshaping the treatment landscape across both hematologic malignancies ...
During the Miami Breast Cancer Conference, CURE discussed ADCs with Dr. Kevin Kalinsky. The treatment landscape for breast cancer is shifting rapidly, driven by the rise of antibody-drug conjugates ...
In a Chinese phase 3 trial of a Bristol Myers Squibb antibody-drug conjugate, progression-free and overall survival were significantly better on izalontamab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results